Sai Life
Sai Life Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #65 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Sai Life Sciences projects a long-term revenue growth guidance of 15% to 20% over a 3-to-5-year horizon. Sai Life Sciences projects mid-term revenue growth of 15% to 20% over a 3-5 year period, emphasizing a longer-term view due to industry lumpiness.
From Sai Life's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Sai Life Sciences projects a long-term revenue growth guidance of 15% to 20% over a 3-to-5-year horizon.
- The company reported a 30% annualized growth last year, indicating strong momentum.
- Growth is expected despite inherent business lumpiness, with a plan to balance capacity expansion and technology investment.
- The CDMO business anticipates better performance in the second half of FY27, driven by new capacity coming online.
- Expanded collaborations via dedicated FTE development contracts and integrated service models with large pharma are expected to deepen customer relationships and pipeline.
2 more points from Sai Life's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sai Life said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- A significant greenfield peptide manufacturing facility near Hyderabad is planned, expected operational by 2028.
- Investment in building pilot scale conjugation facilities for ADCs is underway, spanning discovery and development stages.
- New capacity is being developed for early to mid-stage deliveries at a new greenfield manufacturing site.
- Formulation capabilities are being added, with the facility expected operational within six months, driven by customer interest.
- Expansion includes two production blocks (225 KL each) in Bidar, totaling 450 KL, with the first block on track for H2 FY27.
2 more points from Sai Life's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Life said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Sai Life Sciences Limited has a healthy order book supported by a growing base of large pharmaceutical customers.
- Over 90% of revenue in FY25 and FY26 came from returning customers, reflecting strong repeat orders.
- The company secured six late-phase molecules to its pipeline in the past 15 months, five of which came through large pharma clients with ongoing FTE (Full-Time Equivalent) engagements.
- Dedicated FTE development contracts are expected to augment the pipeline of late-phase and commercial molecules.
- One large pharma collaboration has expanded into a sizable dedicated FTE contract, covering the complete product lifecycle from discovery to commercial manufacturing.
- The discovery capacity expansion facility came on stream in Q1 and is already sold out, indicating strong demand.
2 more points from Sai Life's call on order book
Create a free account to keep reading this call
Sai Life — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹602 Cr, net profit ₹104 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sai Life and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sai Life Q1 FY27 results?
Sai Life Sciences projects a long-term revenue growth guidance of 15% to 20% over a 3-to-5-year horizon. Sai Life Sciences projects mid-term revenue growth of 15% to 20% over a 3-5 year period, emphasizing a longer-term view due to industry lumpiness.
What is Sai Life share price analysis?
Sai Life currently shows a below-average growth signal. The stock trades at a P/E of 84.1 with a market cap of ₹30,940 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sai Life on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.